Literature DB >> 16343885

Post-translational modifications of naturally processed MHC-binding epitopes.

Victor H Engelhard1, Michelle Altrich-Vanlith, Marina Ostankovitch, Angela L Zarling.   

Abstract

A variety of different post-translational modifications of peptides displayed by class I and II MHC molecules have now been described. Some modifications promote the binding of peptides to MHC molecules, and might also influence the ability of the peptide to be produced by antigen processing pathways. In some instances, the antigen processing components themselves are actually responsible for generating post-translational modifications. Finally, evidence is accumulating that modifications can be altered as a consequence of inflammation, transformation, apoptosis and aging. This leads to altered repertories of MHC-associated peptides, which may be important in immune responses associated with autoimmune diseases, infection and cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343885     DOI: 10.1016/j.coi.2005.11.015

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  41 in total

1.  Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.

Authors:  Kenzo Ohara; Takayuki Ohkuri; Takumi Kumai; Toshihiro Nagato; Yui Nozaki; Kei Ishibashi; Akemi Kosaka; Marino Nagata; Shohei Harabuchi; Mizuho Ohara; Kensuke Oikawa; Naoko Aoki; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

Review 2.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

3.  Tumors reveal their secrets to cytotoxic T cells.

Authors:  Nicholas A Williamson; Jamie Rossjohn; Anthony W Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-27       Impact factor: 11.205

4.  The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.

Authors:  Victor H Engelhard
Journal:  Int J Mass Spectrom       Date:  2007-01-01       Impact factor: 1.986

5.  Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.

Authors:  Miguel Marcilla; Adán Alpízar; Manuel Lombardía; Antonio Ramos-Fernandez; Manuel Ramos; Juan Pablo Albar
Journal:  Mol Cell Proteomics       Date:  2013-12-23       Impact factor: 5.911

Review 6.  Post-translationally modified T cell epitopes: immune recognition and immunotherapy.

Authors:  Jan Petersen; Anthony W Purcell; Jamie Rossjohn
Journal:  J Mol Med (Berl)       Date:  2009-09-08       Impact factor: 4.599

7.  Employing a recombinant HLA-DR3 expression system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a genetic, biochemical, and reverse immunological perspective.

Authors:  Eric M Jacobson; Heyi Yang; Francesca Menconi; Rong Wang; Roman Osman; Luce Skrabanek; Cheuk Wun Li; Mohammed Fadlalla; Alisha Gandhi; Vijaya Chaturvedi; Eric P Smith; Sandy Schwemberger; Andrew Osterburg; George F Babcock; Yaron Tomer
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

Review 8.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

9.  Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach.

Authors:  Nicholas T Seyfried; Leanne C Huysentruyt; James A Atwood; Qiangwei Xia; Thomas N Seyfried; Ron Orlando
Journal:  Cancer Lett       Date:  2008-02-20       Impact factor: 8.679

10.  Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations.

Authors:  Nathanael McCurley; Ira Mellman
Journal:  PLoS One       Date:  2010-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.